5,000 Alzheimer's patients monitored for brain side effects of new drug

NCT ID NCT06322667

Recruiting now Knowledge-focused Sponsor: Eisai Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is tracking 5,000 people with early Alzheimer's who are taking the drug lecanemab in regular medical practice. The goal is to see how often brain changes called ARIA occur and how doctors manage treatment when they do. Researchers will also look at infusion reactions. This is an observational study, not a test of whether the drug works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER'S DISEASE

Contacts and locations

Locations

Eisai trial site 1
RECRUITING

Tokyo, Japan
Eisai trial site 2
RECRUITING

Hiroshima, Japan
Eisai trial site 3
RECRUITING

Kyoto, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.